INTRODUCTION

Cervical cancer (CC), the second most common malignancy in females worldwide, is a primary cause of cancer death, leading to about 300,000 deaths each year. Statistically, about 500,000 new cases arise per year, and 85% of the pathologic types are squamous cell carcinoma. In China, CC accounts for 5% of cancer occurrences and 3.8% of mortalities in women. In recent decades, although the cervical cytology screening has facilitated early detection and early treatment, morbidity rates remain high. Worriedly, more and more cases in younger individuals are being recorded. Moreover, the etiology of this cancer is still largely unclear. Thus, many researchers have sought to identify the molecular mechanisms involved in the progression of CC and to seek out more effective tumor therapy strategies.

Family with sequence similarity 83 (FAM83) family members have been shown to possess oncogenic properties, and the expression thereof has been found to be elevated in several human cancer types, including breast cancer. Typically, FAM83 family members are related to poor cancer prognosis. FAM83 member H (FAM83H) is one member of FAM83. Re-
cently, it has been reported that FAM83H controls the organization of the keratin cytoskeleton, as well as the formation of desmosomes. In recent research, up-regulation of FAM83H in cancer tissues, compared to normal samples, has been described. For example, FAM83H has been suggested to contribute to the development of colorectal cancer by regulating the organization of the keratin cytoskeleton. Another study also showed that FAM83H might be an important biomarker that can cause androgen independent prostate cancer progression. Moreover, Kim, et al. have proposed that FAM83H plays important roles in the progression of hepatocellular carcinoma and is a poor prognostic predictor in hepatocellular carcinoma patients. Nevertheless, the exact role of FAM83H in CC has not been studied to date, and the detailed action mechanisms of FAM83H in CC still remain unknown.

In our study, we conducted in vitro assays to investigate the expression and the mechanisms of FAM83H in the progression of CC. Our results demonstrated that FAM83H is involved in CC cell proliferation and migration, suggesting that FAM83H as a potential novel therapeutic target for CC.

MATERIALS AND METHODS

Bioinformatic analysis
The RNA-seq data and clinical data of 306 CC patients and three normal control samples were downloaded from The Cancer Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/tcga). The RNA-seq data were used to analyze the expression of FAM83H in CC patients and normal samples. A total of 304 CC patients with detailed clinical information were divided into low or high expression groups according to the median expression of FAM83H in CC patients and normal samples. A total of 304 CC patients with detailed clinical information were divided into low or high expression groups according to the median expression of FAM83H in CC patients and normal samples. A total of 304 CC patients with detailed clinical information were divided into low or high expression groups according to the median expression of FAM83H in CC patients and normal samples. A total of 304 CC patients with detailed clinical information were divided into low or high expression groups according to the median expression of FAM83H in CC patients and normal samples.

Cell culture and transfection
Human CC cell lines HeLa and SiHa were obtained from the Chinese Academy of Sciences (Shanghai, China). Hacat cells were used as a control. These cells were routinely cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sijiqing Biotec, Hangzhou, China), 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Sigma Chemical Company, Shanghai, China) at 37°C with 5% CO2 in a humidified incubator. Non-adherent cells were washed away after 3 days, and adherent cells were incubated with fresh complete medium. The cells were sub-cultured at the split ratio of 1:2 after reaching confluence.

Two FAM83H-specific small interfering RNAs (si-FAM83H#1: 5'-GAGGAAUGCCACUACAGG-3' and si-FAM83H#2: 5'-CUACAGGAUAUUUAGGGAGGA-3') were synthesized by GenePharma (Shanghai, China). Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) was used for transfection. Twenty-four hours after transfection, the HeLa cells were lysed and then subjected to Real-time Quantitative Reverse Transcription PCR (qRT-PCR) to examine the efficiency of inhibition. HeLa cells transfected with scrambled siRNA control (si-con) were regarded as controls.

RNA extraction and qRT-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) from CC cells transfected with siRNA and the negative controls. The extracted RNA was dissolved using RNAase-free water that was treated with diethyl pyrocarbonate. Next, cDNA was synthesized based on total RNA using PrimeScript RT reagent kit (TaKaRa, Dalian, China). Afterwards, qRT-PCR was conducted to quantify the expression levels of FAM83H. The primers for this gene were as follows: FAM83H, F: 5'-CTGGACCCAGAGATGCCCCCT-3' and R: 5'-CTGGAGGAGATGGCAGACCT-3'. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control (F: 5'-GGAGCGAGATCCCTCCAAAAT-3', R: 5'-GGCTGTGTCAATACTTCTCTGGTTG-3'). The 2-ΔΔCT method was utilized to calculate the relative expression levels.

Cell proliferation and colony formation assays
Cell proliferation ability was assessed using a Cell-Counting Kit 8 (CCK-8) assay, as described by the manufacturer. The HeLa cells were cultured in 96-well plates, and then, 10 μL of CCK-8 solution was added to each well at the indicated time points (24, 48, 72, and 96 h) after transfection. Further, cells were cultured for 2 h at 37°C in a 5% CO2 incubator. Absorbance was measured at 450 nm.

Colony formation was conducted as described previously. Specifically, si-FAM83H and si-control cells were cultured in medium supplemented with 10% FBS, and replacing the medium every four days. Then, the cells were incubated at 37°C in a 5% CO2 incubator for 1 week. Subsequently, 4% paraformaldehyde was used to fix the colonies, and 0.1% crys-
tal violet (Sigma, St. Louis, MO, USA) was applied to stain the colonies. The images of the colonies were photographed. The number of colonies were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The number of colonies in the si-con group was defined as 100%.

**In vitro woundhealing, migration, and invasion assays**

The effect of FAM83H on the migration of HeLa cells was measured using wound-healing assay kits. Wound healing inserts were added into 24-well plates, and the cells were seeded to either side of the insert after 24 h transfection and cultured overnight to form a monolayer. After that, inserts were discarded when an open wound field in the monolayer of cells was generated. Then, cells continued to be cultured for 24 h under standard conditions. Photographs of wound healing were recorded with a phase-contrast microscope at 0 and 24 h after eliminating the inserts.

The migration assay was carried out using a 24-transwell migration chamber with 8-μm pore filters (BD Biosciences, San Jose, CA, USA). HeLa cells were added into the migration chamber where the bottom chamber was filled with 500 μL of complete medium supplemented with 10% FBS. For the invasion assay, 2×10^5 cells were seeded in the upper chamber containing an 8-μm pore Matrigel Invasion Chamber (BD Biosciences, San Jose, CA, USA). Serum-free medium was put into the lower chamber in the invasion assay. The migration and invasion chambers were incubated at 37°C overnight. Thereafter, the migrated or invaded cells on lower surface of the filter were stained with 0.1% crystal violet for 20 min and counted in five microscopic fields for each well.

**Western blotting analysis**

Cells were lysed using RIPA buffer (Beyotime, Jiangsu, China), and protein concentration was measured with Bio-Rad DC protein assay (Bio-Rad, Hercules, CA, USA). Then, a total of 20 μg of protein from the cell lysate was subjected to sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. Subsequently, membranes were blocked with 5% non-fat milk overnight and incubated with the specific primary antibodies (anti-FAM83H, anti-AKT, anti-p-AKT, anti-PI3K, anti-p-PI3K, and anti-GAPDH). Following washing for 30 min with TBST, secondary antibody was used to incubate the membranes in TBST for 2 h at room temperature. After washing, the interested protein signals were captured using Enhanced Chemiluminescence Plus detection kit (Thermo Fisher Scientific, Rockford, IL, USA).

**Statistical analysis**

One-way analysis of variance (ANOVA) was utilized to compare the values of multi-groups. All experiments were carried out in triplicate. Statistical analysis was performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA). p values <0.05 were considered statistically significant.

**RESULTS**

**FAM83H elevated in CC**

By retrieving the data in the TCGA database and GEPIA database, we characterized FAM83H expression in CC (Fig. 1A-C). Results revealed marked up-regulation of FAM83H expression in CC tissues, compared to normal tissues (Fig. 1A-C).

In order to verify the bioinformatics results, we next measured the expression of FAM83H in the CC cell lines SiHa and HeLa using qRT-PCR. Consistent with the bioinformatics results, FAM83H expression was remarkably up-regulated in SiHa and HeLa cell lines when compared with normal Hacat cells (p<0.001) (Fig. 1D). We found that expression levels in HeLa cells were significantly higher than those in SiHa cells. Thus, in our study, we selected HeLa cells for subsequent analysis.

**FAM83H correlated with clinical characteristics of CC**

We then analyzed the relationship between FAM83H and clinical pathological characteristics of CC based on the data obtained from TCGA database. The clinicopathological characteristics of CC patients are shown in Table 1. We found that high FAM83H expression in CC was associated with clinical stage (p=0.008), pathologic tumor (p=0.023), and pathologic node (p=0.038).

**FAM83H overexpression related to poor prognosis in CC**

To further investigate the prognostic value of FAM83H, we performed Kaplan-Meier analysis based on the TCGA, GEPIA, and the Human Protein Atlas databases. The results showed that high FAM83H expression is associated with worse OS in patients with CC based on the TCGA data with the median of FAM83H expression used as the cutoff (Fig. 1E, p=0.027). Although the difference was not significant, we also noted that high FAM83H expression was associated with lower survival rate to some extent in the GEPIA database (Fig. 1F, p=0.053). From the Human Protein Atlas database, we found that higher expression of FAM83H was associated with shorter survival with the best cut-off point (Fig. 1G, p=0.004).

Next, we performed univariate and multivariate proportional hazards analyses to identify independent prognostic factors for survival in CC patients. Univariate analysis suggested that FAM83H expression (p=0.028), clinical stage (p=0.001), pathologic tumor (p=0.001), pathologic metastasis (p=0.020), and pathologic node (p=0.003) were significantly related to the OS of CC patients (Table 2). Multivariate analysis demonstrated that pathologic tumor was an independent prognostic factor for the OS of CC patients (p=0.033). However, FAM83H expression could not be regarded as independent prognostic factor for the OS of CC patients (p=0.716). Above
Fig. 1. FAM83H over-expression is associated with poor prognosis of CC. (A) FAM83H expression at mRNA level in CC tissues in TCGA database. (B) FAM83H expression at mRNA level in CC tissues in GEPIA database (match TCGA normal data). (C) FAM83H expression at mRNA level in CC tissues in GEPIA database (match TCGA normal and GTEx data). (D) Real-time Quantitative Reverse Transcription PCR used to measure the expression level of FAM83H in human CC cell lines (SiHa and HeLa). The expression of FAM83H was significantly higher in CC cells relative to control cells. (E) Kaplan-Meier curves of OS of CC patients in TCGA database. Patients were sub-grouped into high (n=152) or low (n=152) groups based on the median of FAM83H expression. (F) Kaplan-Meier curves of OS of CC patients in GEPIA database. Patients were sub-grouped into high (n=146) or low (n=146) groups based on the median of FAM83H expression. (G) Kaplan-Meier curves of OS of CC patients in the Human Protein Atlas database. Patients were sub-grouped into high (n=224) or low (n=67) groups based on best cut-off point. *p<0.05, **p<0.01. FAM83H, family with sequence similarity 83 member H; CC, cervical cancer; TCGA, The Cancer Genome Atlas; GEPIA, Gene Expression Profiling Interactive Analysis; OS, overall survival; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; TPM, transcripts per million; HR, hazard ratio.
all, the results indicated that, while the expression of FAM83H is significantly associated with OS in CC patients, it cannot be considered an independent prognostic factor.

**Knockdown of FAM83H inhibits the proliferation and growth of HeLa cells**

To identify the roles of FAM83H in CC cells, si-FAM83H was transfected into HeLa cells to determine its effect on the proliferation ability of HeLa cells. In the current study, the transfection efficiency of both si-FAM83H #1 and si-FAM83H #2 was >80% (Fig. 2). In addition, a greater decrease in FAM83H expression was observed in the si-FAM83H #1 group, compared with the si-FAM83H #2. Thus, si-FAM83H #1 was used in subsequent experiments.

CCK-8 results suggested that the knockdown of FAM83H effectively inhibited the proliferation of HeLa cells (Fig. 3) at 48 h ($p<0.05$), 72 h ($p<0.001$), and 96 h ($p<0.001$). Likewise, colony formation assay showed that FAM83H silencing reduced the colony numbers of HeLa cells ($p<0.001$) (Fig. 4).

**Knockdown of FAM83H inhibits the migration and invasion of HeLa cells**

Following 24 h scratch formation in the cell monolayer, the wound in the FAM83H knockdown cells was wider, compared with that in the control cells, suggesting that knockdown of FAM83H significantly inhibits HeLa cell migration (Fig. 5A). Subsequently, we also utilized transwell assay to investigate

### Table 1. Relationships between FAM83H Expression and Clinicopathologic Features in Cervical Cancer Patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Expression of FAM83H</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>0.675</td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>118</td>
<td>121</td>
</tr>
<tr>
<td>≥60</td>
<td>34</td>
<td>31</td>
</tr>
<tr>
<td>Grade</td>
<td>0.521</td>
<td></td>
</tr>
<tr>
<td>G1+G2</td>
<td>75</td>
<td>78</td>
</tr>
<tr>
<td>G3</td>
<td>63</td>
<td>56</td>
</tr>
<tr>
<td>Clinical-stage</td>
<td>0.008*</td>
<td></td>
</tr>
<tr>
<td>I+II</td>
<td>127</td>
<td>104</td>
</tr>
<tr>
<td>III+IV</td>
<td>24</td>
<td>42</td>
</tr>
<tr>
<td>Pathologic-T</td>
<td>0.023*</td>
<td></td>
</tr>
<tr>
<td>T1+T2</td>
<td>117</td>
<td>94</td>
</tr>
<tr>
<td>T3+T4</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>Pathologic-N</td>
<td>0.038*</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>79</td>
<td>54</td>
</tr>
<tr>
<td>N1</td>
<td>26</td>
<td>34</td>
</tr>
<tr>
<td>Pathologic-M</td>
<td>0.514</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>65</td>
<td>51</td>
</tr>
<tr>
<td>M1</td>
<td>7</td>
<td>3</td>
</tr>
</tbody>
</table>

FAM83H, family with sequence similarity 83 member H. Since the clinical pathological information was not complete in some cases, the number of cases in grade, Clinical-stage, Pathologic-T, N and M are less than 304, and the number of cases are different.

* $p<0.05$.

### Table 2. Univariate and Multivariate Analyses of Clinical Prognostic Factors of Cervical Cancer

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$p$ value</td>
<td>HR</td>
</tr>
<tr>
<td>FAM83H (low/high)</td>
<td>0.028</td>
<td>1.691</td>
</tr>
<tr>
<td>Clinical-stage (I+II/III+IV)</td>
<td>0.001</td>
<td>2.286</td>
</tr>
<tr>
<td>Pathologic-T (T1+T2/T3+T4)</td>
<td>&lt;0.001</td>
<td>3.613</td>
</tr>
<tr>
<td>Pathologic-M (M0/M1)</td>
<td>0.020</td>
<td>3.671</td>
</tr>
<tr>
<td>Pathologic-N (N0/N1+N2+N3)</td>
<td>0.003</td>
<td>2.807</td>
</tr>
<tr>
<td>Age (&lt;60/≥60)</td>
<td>0.054</td>
<td>1.641</td>
</tr>
<tr>
<td>Grade (G1+G2/G3+G4)</td>
<td>0.681</td>
<td>0.896</td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence interval; FAM83H, family with sequence similarity 83 member H.

---

**Fig. 2. FAM83H expression in HeLa cells transfected with siRNA FAM83H 1# and siRNA FAM83H 2# were measured by Real-Time Quantitative Reverse Transcription PCR (A) and Western blotting (B and C). * $p<0.01$ compared to the si-con group. FAM83H, family with sequence similarity 83 member H; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.**
the potential effects of FAM83H knockdown on cell migration and invasion. We observed that, after FAM83H silencing, the migration and invasion of CC cells were effectively inhibited (p<0.001) (Fig. 5B and C). Overall, these data indicated that FAM83H promotes CC cell migration and invasion.

Knockdown of FAM83H inhibits the activation of PI3K signaling pathway
To further describe the specific molecular mechanism of FAM83H-regulated proliferation and migration of CC cells, we used Western blotting to explore the candidate targets of FAM83H, by which we selected the PI3K signaling pathway (AKT, p-AKT, PI3K, p-PI3K) as a target, since the PI3K pathway plays key roles in mediating proliferation and migration. Fig. 6 shows that knockdown of FAM83H remarkably inhibited the expression levels of p-AKT and p-PI3K in CC cells (p<0.001), but did not influence total PI3K and AKT expression levels.

Fig. 3. Knockdown of FAM83H inhibits growth and viability of HeLa cells. CCK-8 assay showing viability of transfected HeLa cells at 24, 48, 72, and 96 h. *p<0.05 compared to control, **p<0.001 compared to control. CCK-8, Cell-Counting Kit 8; FAM83H, family with sequence similarity 83 member H; OD, optical density.

Fig. 4. Knockdown of FAM83H decreases colony formation of HeLa cells. (A) Representative images of colony formation assay (x2). The clones were dyed by 0.1% crystal violet. (B) Quantification of the colony numbers. *p<0.001 compared to control. FAM83H, family with sequence similarity 83 member H.

Fig. 5. Analysis of wound-healing (A; ×100) and transwell assay [B (×200) and C]. Cells were dyed by 0.1% crystal violet. In HeLa cells transfected with si-FAM83H, the invasion and migration were significantly decreased compared to the cells transfected with scrambled si-RNA (si-con). *p<0.001 compared to control. FAM83H, family with sequence similarity 83 member H.

Fig. 6. The expression of PI3K/AKT pathway related proteins. After FAM83H silencing, the expression of p-AKT and p-PI3K were all reduced significantly. (A) The expression of PI3K pathway related proteins were determined by Western blot. (B) Quantification of the protein expression levels in (A). *p<0.001 compared to control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; FAM83H, family with sequence similarity 83 member H.
DISCUSSION

In our study, we investigated the role of FAM83H in CC and provided evidence suggesting that FAM83H plays an oncogenic role in CC. The oncogenic role of FAM83H is supported by the expression of relatively higher levels of FAM83H in CC, compared with normal tissues obtained from TCGA database. Consistent with bioinformatics results, overexpression of FAM83H was also observed in CC cells. Additionally, high FAM83H expression was found to be closely correlated with shorter survival in CC patients. As FAM83H has been found to be overexpressed in multiple other tumor types (e.g., colorectal cancer), these data strongly support that FAM83H itself is an important oncogene in CC.

In depth, we studied the role and significance of FAM83H in CC cell proliferation and migration. Knockdown of FAM83H effectively inhibited the proliferation and growth of HeLa cells. Colony-formation assay demonstrated that the expression of FAM83H affects the colony-formation capacity of HeLa cells. Of note, a previous study demonstrated that knockdown of FAM83H in LNCaP cells suppressed colony formation. So far, FAM83H has been reported to mediate several target proteins in cell migration and proliferation. Meanwhile, studies have suggested that the PI3K pathway plays key roles in mediating proliferation and migration. Accordingly, we investigated whether PI3K was affected by FAM83H in CC cells using Western blotting.

PI3K/AKT signaling pathway has been implicated in the physiological functions of human malignant tumors, including ovarian, breast, and pancreatic cancer. AKT activity is triggered by PI3K, and AKT activation induces cell survival, migration, and metabolism through phosphorylation of various physiological factors. It is noteworthy that sustained AKT activity in CC cells (HeLa and Caski) may facilitate their growth and survival. Several studies have reported that the PI3K/AKT pathway is activated in CC. For example, in a Korean study of 27 CC patients (18 without and nine with recurrence), p-AKT expression was related to local recurrence after primary radiotherapy. Another study of 46 paraffin-embedded specimens without associated clinical outcome data, p-AKT staining was positive in 39 (85%) of the samples. Liu et al. suggested that inhibition of Akt/mTOR/p70S6K translational machinery results in the downregulation of MMP-9 and urokinase plasminogen activator, playing an anti-metastatic role. In the current study, Western blot analysis revealed significant decreases in the activity of p-AKT and p-PI3K in si-FAM83H-transfected CC cells. Accordingly, we inferred that FAM83H promotes CC growth and migration, at least partially by mediating PI3K/AKT signaling.

To our best knowledge, this is the first study to report that FAM83H increases cell proliferation, colony formation, migration, and invasion of CC cells. Our work suggests that inhibition of FAM83H might be a potential therapeutic strategy in the management of CC. However, we must take into consideration several limitations. To begin with, we did not use clinical samples collected by ourselves to detect FAM83H expression in CC tissues. Secondly, animal models of tumors were not constructed to verify our results obtained in the cell experiments. Nevertheless, our study provides evidence of use to further exploring the molecular mechanisms of CC and developing candidate targets for the treatment thereof.

AUTHOR CONTRIBUTIONS

Conceptualization: Chao Chen and Jia Zhou. Data curation: Chao Chen and Hua-Feng Li. Formal analysis: Yu-Jie Hu. Investigation: Chao Chen, Hua-Feng Li, Yu-Jie Hu, Meng-Jie Jiang, and Qing-Sheng Liu. Methodology: Chao Chen. Project administration: Chao Chen and Jia Zhou. Software: Hua-Feng Li and Yu-Jie Hu. Supervision: Jia Zhou. Validation: Meng-Jie Jiang and Qing-Sheng Liu. Visualization: Chao Chen. Writing—original draft: Chao Chen. Writing—review and editing: Jia Zhou.

ORCID iDs

Chao Chen https://orcid.org/0000-0002-0342-4170
Hua-Feng Li https://orcid.org/0000-0001-9274-942X
Yu-Jie Hu https://orcid.org/0000-0001-6328-175X
Meng-Jie Jiang https://orcid.org/0000-0001-5129-676X
Qing-Sheng Liu https://orcid.org/0000-0003-1351-1443
Jia Zhou https://orcid.org/0000-0001-6143-9584

REFERENCES

10. Nalla AK, Williams TF, Collins CP, Rae DT, Trobridge GD. Lentiv-


